从资金流向上来看，当日中药板块主力资金净流入7067.51万元，游资资金净流出1.31亿元，散户资金净 流入6030.46万元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600436 | 片仔瘦 | 7033.61万 | 11.36% | -554.04万 | -0.89% | -6479.57万 | -10.47% | | 600518 | 康美药业 | 3587.72万 | 12.09% | -2642.43万 | -8.90% | -945.29万 | -3.19% | | 600085 | 同仁堂 | 3340.39万 | 9.95% | -1916.58万 | -5.71% | -1423.81万 | -4.24% | | 603858 | 步长制药 | 3071.09万 | 16.61% | -96.93万 | -0.52% | -2974.16万 | -16.09% ...

随着2025年谢幕，A股公司治理的一张"底牌"正在被翻开。 《中国上市公司董责险市场报告（2026）》（下称《报告》）指出，2025年底A股上市公司董事、监事 及高级管理人员责任保险的整体渗透率，已历史性地突破了32%； 在过去一年，A股共有643家上市公司披露董责险购买计划，同比增长近2成。 数据的攀升并非孤立的数字游戏。 自2024年7月新《公司法》正式实施以来，资本市场对高管履职风险认知，正在重构； 将时间轴拉长，A股上市公司的董责险渗透率增长，曾经历过两次显著的加速。 第一次爆发，更像是上市公司在康美药业案落地后，被激发的"应激反应"。 2021年，我国首例"特别代表人诉讼"案震动业界。 在一审判决中，康美药业因年报虚假陈述，被判向投资者赔偿24.59亿元。 从几年前康美药业案后的恐慌性投保，到如今法律制度倒逼的常态化配置，董责险正在完成从"可选消 费"向"刚性标配"的惊险一跃。 然而，硬币的另一面仍旧充满悖论。 理赔端，证券虚假陈述判赔金额动辄数亿、风险水位不断上涨，但承保端，市场平均费率却一路下探至 千分之五以下，陷入低价竞争的泥潭。 这种"高危低价"的错配能维持多久？ 一场关于风险定价的博弈，正 ...

Group 1 - The average stock price of A-shares is 14.84 yuan, with 29 stocks priced below 2 yuan, the lowest being *ST Aowei at 0.73 yuan [1] - Among the low-priced stocks, 8 are ST stocks, accounting for 27.59% of the total [1] - In terms of market performance, 26 of the low-priced stocks increased in price, with *ST Changyao, *ST Lifang, and Yabo shares leading the gains at 19.48%, 13.91%, and 10.06% respectively [1] Group 2 - The stock price rankings of low-priced stocks show *ST Aowei at 0.73 yuan with a daily decline of 5.19%, while *ST Changyao and *ST Lifang have daily increases of 19.48% and 13.91% respectively [1] - The trading volume for *ST Changyao is notable with a turnover rate of 19.92%, while *ST Lifang has a turnover rate of 26.78% [1] - Other low-priced stocks include *ST Jinke at 1.49 yuan and Chongqing Steel at 1.54 yuan, with respective daily changes of 0.68% and 2.67% [1]

Market Overview - The Chinese traditional medicine sector saw a slight increase of 0.11% on January 12, with Wanbangde leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up by 1.09%, while the Shenzhen Component Index closed at 14366.91, up by 1.75% [1] Stock Performance - Wanbangde (002082) closed at 16.56, with a significant increase of 10.03% and a trading volume of 376,100 shares, amounting to 615 million yuan [1] - Zhenbaodao (603567) rose by 4.62% to close at 9.74, with a trading volume of 185,700 shares [1] - Taiji Group (600129) increased by 2.79% to 19.16, despite a decrease in trading volume of 146,600 shares [1] - Renhe Pharmaceutical (000650) and other companies also showed positive growth, with Renhe closing at 6.18, up by 2.15% [1] Capital Flow - The traditional medicine sector experienced a net outflow of 550 million yuan from institutional investors, while retail investors contributed a net inflow of 460 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Wanbangde saw a net inflow of 95.22 million yuan from institutional investors, but a net outflow from retail investors of 67.16 million yuan [3] - Other companies like Jianxin Pharmaceutical (002412) and Jilin Aodong (000623) also experienced varying degrees of net inflows and outflows from different investor categories [3]

Core Viewpoint - The company has appointed new auditors for the 2025 fiscal year, ensuring continuity and compliance in its financial reporting and internal control audits [1]. Group 1: Auditor Appointment - The company’s board approved the reappointment of Zhongshun Zhonghuan Accounting Firm as the auditor for the 2025 fiscal year [1]. - The signing auditors are Wu Zhihao and Sheng Peiyong, while Zhao Liang will serve as the quality control review partner [1]. Group 2: Auditor Background - Sheng Peiyong became a certified public accountant in 2022 and has been involved in auditing listed companies since 2012, starting to practice at Zhongshun Zhonghuan in 2024 [2]. - Zhao Liang became a certified public accountant in 2020 and has been auditing listed companies since 2018, also starting to practice at Zhongshun Zhonghuan in 2020 [2]. Group 3: Independence and Integrity - The newly appointed auditors and quality control review partner have no record of criminal or administrative penalties in the last three years [2]. - There are no violations of the independence requirements as per the Code of Ethics for Chinese Certified Public Accountants [3]. Group 4: Impact on the Company - The transition to the new auditors will be orderly, and it is not expected to adversely affect the company's financial reporting and internal control audit for 2025 [4].

Core Viewpoint - Kangmei Pharmaceutical (600518) announced on an interactive platform that as of September 30, 2025, the total number of shareholders will be 300,150 [1] Summary by Relevant Categories Company Information - Kangmei Pharmaceutical is projecting a total of 300,150 shareholders by September 30, 2025 [1]

Group 1 - The core product of the company, Baoning Banxia Granules, is a unique offering in the national market and is a key traditional Chinese medicine product [1] - The product is primarily used for treating symptoms such as wind-cold cough, wheezing, persistent cough, stubborn phlegm, and cough in the elderly [1]

Group 1 - The core point of the article is that Kangmei Pharmaceutical (600518) confirmed that its wholly-owned subsidiary, Kangmei Times (Guangdong) Development Co., Ltd., is included in the consolidated financial statements [1] Group 2 - Kangmei Pharmaceutical responded to investor inquiries on an interactive platform regarding its financial reporting [1] - The financial statements of Kangmei Times have been integrated into the company's overall financial reporting [1]

Core Viewpoint - Kangmei Pharmaceutical is leveraging internet and IoT technologies to transform traditional pharmaceutical logistics, providing a comprehensive range of pharmaceutical services to patients [2] Company Summary - The company’s smart pharmacy offers services including traditional Chinese medicine decoction, Chinese medicine pieces, Western and Chinese medicine preparation, medicinal paste production, home delivery, and pharmaceutical consultations [2]

Group 1 - The core viewpoint of the article is that Kangmei Pharmaceutical plans to develop a shareholder return plan based on various factors including profit distribution conditions, actual operating status, cash flow levels, and future development needs [2] Group 2 - The company has indicated that it will consider multiple factors when formulating its shareholder return plan to reward investors [2]